←
MSD2,148 posts
MSD avatar

MSD

@MSDInvents

We aspire to be the premier research-intensive biopharmaceutical company.

◷ Joined October 2016▧ 1,710 Photos and videos
MSD avatar
MSD@MSDInvents·Nov 9

New Phase 2b data for an investigational therapy in adults with #MASH were presented today and published in @TheLancet. Learn more about the findings and our ongoing research in this chronic, progressive liver disease: go.msd.com/~d9w

0:06
MSD avatar
MSD@MSDInvents·Oct 10

Today, we’re presenting data from our Phase 2b/3 trial of an investigational drug in patients with diabetic macular edema (DME). Learn more: go.msd.com/~2va

Post attachment
MSD avatar
MSD@MSDInvents·Sep 30

Today at #EADVCongress, we shared positive Phase 2b results evaluating our investigational anti-TL1A biologic in adults with moderate to severe hidradenitis suppurativa (HS). Learn more: go.msd.com/~nel

0:09
MSD avatar
MSD@MSDInvents·Jul 24

Today we announced our initial post-approval access plans for our investigational HIV prevention option. We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can be accessed by those who need it in low- and middle-income countries. Learn more: go.msd.com/~3wv

0:22
MSD avatar
MSD@MSDInvents·May 7

Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: go.msd.com/~q3y

0:17
MSD avatar
MSD@MSDInvents·May 5

Today, MSD completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more: go.msd.com/~0bd

0:26
MSD avatar
MSD@MSDInvents·Apr 22

We’re proud to partner with Google Cloud to help shape the future of biopharmaceutical innovation with AI-enabled enterprise transformation. This collaboration is about unlocking new value: accelerating discovery, modernizing how we work and empowering our teams to focus on the highest-impact science and solutions for patients. Learn more about the landmark partnership: go.msd.com/~7q2

0:35
MSD avatar
MSD@MSDInvents·Apr 2

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: go.msd.com/~n4o #ophthalmology

0:22
MSD avatar
MSD@MSDInvents·Mar 30

We’re sharing Phase 3 results of our investigational oral macrocyclic peptide. Learn more: go.msd.com/~lx0

0:11
MSD avatar
MSD@MSDInvents·Mar 25

Today, we announced an agreement to acquire Terns Pharmaceuticals, adding a potential best-in-class candidate for the treatment of certain patients with chronic myeloid #leukemia (#CML) to our growing #hematology pipeline: go.msd.com/~dpo9lg

0:27